OrbiMed Portfolio holdings
OrbiMed is an investment manager focused exclusively on healthcare, running public equity, private equity and private credit and royalty funds. The firm traces its origins to 1989, when Viren Mehta and Samuel Isaly, both pharmaceutical analysts at the bank S.G Warburg, set up the research and money-management firm Mehta & Isaly; in 1998 it split in two, with Isaly forming OrbiMed and Mehta forming Mehta Partners. Its public equity side covers long/short funds built around corporate events as well as closed-end investment trusts, and OrbiMed launched its first dedicated venture capital fund in 2000 and its first royalty and credit fund in 2011. Carl Gordon, Carter Neild and Geoffrey Hsu form the committee that leads the firm, which is owned and controlled by eight members.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
+$304M |
| 2 |
Elevance Health
ELV
|
+$123M |
| 3 |
Dentsply Sirona
XRAY
|
+$102M |
| 4 |
AGN
Allergan plc
AGN
|
+$95.1M |
| 5 |
Inspire Medical Systems
INSP
|
+$78.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$185M |
| 2 |
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
|
+$154M |
| 3 |
AbbVie
ABBV
|
+$145M |
| 4 |
Tenet Healthcare
THC
|
+$119M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$69.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.95% |
| 2 | Miscellaneous | 1.43% |
| 3 | Financials | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
| $388M | 4.63% |
3,124,603
-143,672
| -4% | -$16.8M |
2013 Q2
20 quarters
|
|
2
Biogen
BIIB
$37.5B
| $339M | 4.04% |
1,167,900
+127,500
| +12% | +$35.8M |
2013 Q2
20 quarters
|
|
|
TCDA
3
DELISTED
Tricida, Inc. Common Stock
TCDA
| $326M | 3.88% |
+10,889,280
| New | +$304M |
2018 Q2
0 quarters
|
|
4
Boston Scientific
BSX
$60.8B
| $313M | 3.73% |
9,574,695
-803,100
| -8% | -$24.2M |
2014 Q1
17 quarters
|
|
5
Vertex Pharmaceuticals
VRTX
$142B
| $305M | 3.63% |
1,792,600
-62,000
| -3% | -$9.6M |
2013 Q2
20 quarters
|
|
6
Ascendis Pharma A/S
ASND
$16.5B
| $294M | 3.5% |
4,413,291
+1,045,976
| +31% | +$68.8M |
2015 Q1
13 quarters
|
|
7
Merck
MRK
$369B
| $284M | 3.39% |
4,904,640
-637,394
| -12% | -$36M |
2016 Q1
9 quarters
|
|
|
AGN
8
DELISTED
Allergan plc
AGN
| $214M | 2.56% |
1,286,205
+592,600
| +85% | +$95.1M |
2013 Q2
20 quarters
|
|
|
CELG
9
DELISTED
Celgene Corp
CELG
| $204M | 2.44% |
2,570,650
-63,600
| -2% | -$5.28M |
2013 Q2
20 quarters
|
|
10
Jazz Pharmaceuticals
JAZZ
$14B
| $179M | 2.14% |
1,040,100
| – | – |
2013 Q2
20 quarters
|
|
|
WMGI
11
DELISTED
Wright Medical Group Inc
WMGI
| $164M | 1.96% |
6,322,668
-529,400
| -8% | -$12.1M |
2014 Q3
15 quarters
|
|
12
Puma Biotechnology
PBYI
$538M
| $162M | 1.93% |
2,732,881
+91,220
| +3% | +$5.29M |
2014 Q2
16 quarters
|
|
|
CMTA
13
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| $137M | 1.64% |
10,425,225
| – | – |
2017 Q3
3 quarters
|
|
14
Viatris
VTRS
$21.9B
| $134M | 1.6% |
3,702,800
+1,868,500
| +102% | +$73.3M |
2017 Q1
5 quarters
|
|
|
15
Bristol-Myers Squibb
BMY
$128B
| $132M | 1.57% |
2,380,300
-1,295,000
| -35% | -$69.9M |
2013 Q2
20 quarters
|
|
|
16
Regeneron Pharmaceuticals
REGN
$95.5B
| $129M | 1.53% |
372,500
-590,400
| -61% | -$185M |
2013 Q2
20 quarters
|
|
|
AERI
17
DELISTED
Aerie Pharmaceuticals
AERI
| $127M | 1.52% |
1,884,100
| – | – |
2016 Q3
7 quarters
|
|
18
Edwards Lifesciences
EW
$53B
| $127M | 1.51% |
2,612,700
-461,100
| -15% | -$21.5M |
2016 Q1
9 quarters
|
|
|
19
Elevance Health
ELV
$91.1B
| $127M | 1.51% |
+531,800
| New | +$123M |
2018 Q2
0 quarters
|
|
20
Alnylam Pharmaceuticals
ALNY
$22.1B
| $125M | 1.49% |
1,265,966
| – | – |
2017 Q1
5 quarters
|
|
21
Thermo Fisher Scientific
TMO
$258B
| $121M | 1.44% |
583,500
+194,100
| +50% | +$41.2M |
2013 Q2
20 quarters
|
|
22
DaVita
DVA
$12B
| $117M | 1.4% |
1,689,400
+129,800
| +8% | +$8.67M |
2017 Q4
2 quarters
|
|
|
IMMU
23
DELISTED
Immunomedics Inc
IMMU
| $117M | 1.4% |
4,944,573
-766,201
| -13% | -$15.4M |
2015 Q3
11 quarters
|
|
24
Agilent Technologies
A
$49.3B
| $117M | 1.39% |
1,885,100
-951,800
| -34% | -$62.1M |
2013 Q2
20 quarters
|
|
25
DELISTED
Amicus Therapeutics
FOLD
| $110M | 1.32% |
7,072,500
| – | – |
2017 Q4
2 quarters
|
|
Similar funds
OrbiMed's Q2 2018 Portfolio in Review
As of Q2 2018, OrbiMed held 161 positions worth $8.38B, up 4% from $8.07B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
OrbiMed's Q2 2018 filing shows 20 new, 28 increased, 35 reduced and 14 closed positions. Its largest new stake was Tricida, Inc. Common Stock: 10,889,280 shares worth $326M. The largest sale was Regeneron Pharmaceuticals, an estimated $185M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.
- OrbiMed's largest Q2 2018 buy was Tricida, Inc. Common Stock: 10,889,280 shares worth $326M.
- OrbiMed added most to Dentsply Sirona in Q2 2018, an estimated $102M increase.
- OrbiMed's biggest Q2 2018 reduction was Regeneron Pharmaceuticals, cutting an estimated $185M.
- OrbiMed fully exited ARMO BioSciences, Inc. Common Stock in Q2 2018, selling an estimated $154M.
- OrbiMed's ten largest holdings make up 34% of its $8.38B portfolio in Q2 2018.
- OrbiMed opened 20 new positions and closed 14 in Q2 2018.
- OrbiMed's portfolio value rose 4% quarter-over-quarter to $8.38B.
Based on OrbiMed's 13F filing for Q2 2018, filed 14 Aug 2018.